Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Effectiveness of rivastigmine in Alzheimer's disease. Improvements in functional ability remain unestablished.

Literature DB >> 10473490

Effectiveness of rivastigmine in Alzheimer's disease. Improvements in functional ability remain unestablished.

P Bentham, R Gray, E Sellwood, J Raftery.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 1999 PMID： 10473490 PMCID： PMC1116501 DOI： 10.1136/bmj.319.7210.640a

Source DB: PubMed Journal: BMJ ISSN： 0959-8138

× No keyword cloud information.

6 in total

1. Acetylcholinesterase inhibitors for Alzheimer's disease.

Authors: L Flicker
Journal: BMJ Date: 1999-03-06

2. Adjunctive therapy in epilepsy: a cost-effectiveness comparison of two AEDs.

Authors: C E Selai; K Smith; M R Trimble
Journal: Seizure Date: 1999-02 Impact factor: 3.184

3. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.

Authors: M Rösler; R Anand; A Cicin-Sain; S Gauthier; Y Agid; P Dal-Bianco; H B Stähelin; R Hartman; M Gharabawi
Journal: BMJ Date: 1999-03-06

4. First International Pharmacoeconomic Conference on Alzheimer's Disease: report and summary.

Authors: P J Whitehouse; B Winblad; D Shostak; A Bhattacharjya; M Brod; H Brodaty; A Dor; H Feldman; F Forette; S Gauthier; J Hay; C Henke; S Hill; V Mastey; P Neumann; B O'Brien; K Pugner; M Sano; T Sawada; R Stone; A Wimo
Journal: Alzheimer Dis Assoc Disord Date: 1998-12 Impact factor: 2.703

5. Measurement of quality-of-life changes in patients with Alzheimer's disease.

Authors: R DeJong; O W Osterlund; G W Roy
Journal: Clin Ther Date: 1989 Jul-Aug Impact factor: 3.393

6. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group.

Authors: M J Knapp; D S Knopman; P R Solomon; W W Pendlebury; C S Davis; S I Gracon
Journal: JAMA Date: 1994-04-06 Impact factor: 56.272

6 in total

1. Effectiveness of rivastigmine in Alzheimer's disease. Participation in trials should be based on clinical uncertainty, not enforcement.

Authors: R Bullock; P Passmore; D Wilkinson; R Howard; R Jones
Journal: BMJ Date: 2000-02-19

Review 2. Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease.

Authors: H M Lamb; K L Goa
Journal: Pharmacoeconomics Date: 2001 Impact factor: 4.981

3. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group.

Authors: G K Wilcock; S Lilienfeld; E Gaens
Journal: BMJ Date: 2000-12-09